LexaGene Holdings Inc (CVE:LXG, OTCMKTS:LXXGF) is at the leading edge of med-tech in pioneering the first open-access fully-automated pathogen detection platform for use in diagnostics and sample analysis.
While its MiQLab doesn’t have regulatory sign-off for human clinical diagnostics, LexaGene is pursuing an FDA emergency use authorization for Covid testing, which would open a whole new window of opportunity.
In the meantime, it recently launched an early access program for its MiQLab aimed at the veterinary and open-access markets.
To hear more from CEO and founder Jack Regan, sign up for the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.
About the event:
- Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
- We look beyond the numbers and meet the people creating the value for shareholders
- Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
- You can watch the event afterwards on our YouTube channel